Sidharth Sharma
Psychiatry · San Ramon, CANPI 1396069050
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 409 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,792 and has fallen 93.0% since, to $336 in 2021. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$1K
- Sunovion Pharmaceuticals Inc.$731
- Neurocrine Biosciences, Inc.$560
- Alkermes, Inc.$427
- Takeda Pharmaceuticals U.S.A., Inc.$387
- plus $2K from 15 others
What the payments were for
- Food & beverage$7,26498%
- Education$1572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 83 | $1,609 |
| AbbVie(2 entities) | 61 | $1,379 |
| Sunovion Pharmaceuticals Inc. | 50 | $731 |
| Neurocrine Biosciences, Inc. | 45 | $560 |
| Alkermes, Inc. | 21 | $427 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $387 |
| Ironshore Pharmaceuticals Inc. | 7 | $371 |
| Lundbeck LLC | 29 | $346 |
| Johnson & Johnson | 17 | $328 |
| Teva Pharmaceuticals USA, Inc. | 9 | $226 |
| Shire North American Group Inc | 18 | $195 |
| Vanda Pharmaceuticals Inc. | 9 | $189 |
| Jazz Pharmaceuticals Inc. | 10 | $148 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $128 |
| Neos Therapeutics, LP | 8 | $121 |
| Eisai Inc. | 5 | $92 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $74 |
| Brainsway USA Inc | 1 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Vertical Pharmaceuticals, LLC | 2 | $30 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$839
- REXULTI$703
- ARISTADA$500
- Jornay PM 20mg capsules (Bottle of 100)$298
- LATUDA$245
- CAPLYTA$128
- ARISTADA INITIO$125
- SPRAVATO$124
- INGREZZA$121
How this compares
$7,421 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Chlorpromazine Hcl | 14 | $29,427 |
| Haloperidol | 17 | $887 |
| Divalproex Sodium | 15 | $676 |
| Benztropine Mesylate | 21 | $432 |
| Clonazepam | 18 | $357 |
| Mirtazapine | 14 | $330 |
| Lorazepam | 21 | $199 |
| Lithium Carbonate | 12 | $186 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in San Ramon
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.